Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FLAG-347
- Development stage
- Preclinical
- Lead developer
- FLAG Therapeutics
- Modality
- Small Molecules
01
Overview
FLAG-347 is a small molecule drug candidate initially developed by Duquesne University of The Holy Spirit and currently under development by FLAG Therapeutics. It is being investigated primarily for the treatment of neoplasms, with a focus on pancreatic cancer. The drug is in preclinical development and has also been associated with potential applications in digestive system disorders as well as endocrinology and metabolic diseases. While specific details about its mechanism of action are not publicly disclosed, related compounds from the same developer have demonstrated anti-angiogenic and anti-tubulin activities, suggesting that FLAG-347 may act through similar pathways[2][4].
Beyond the preview
Go deeper on FLAG-347.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FLAG-347.